These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 2202462

  • 1. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.
    Woods WG, Ramsay NK, Weisdorf DJ, Haake R, Vallera DA, Kim TH, Lasky L, Nesbit ME, Bostrom B, Uckun F.
    Bone Marrow Transplant; 1990 Jul; 6(1):9-16. PubMed ID: 2202462
    [Abstract] [Full Text] [Related]

  • 2. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, Holmes W, Becker P, Roberts KB, Rappeport JM.
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
    Moussalem M, Esperou Bourdeau H, Devergie A, Baruchel A, Ribaud P, Socie G, Parquet N, Traineau R, Hirsch I, Schaison G.
    Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG, Warkentin PI, Strandjord SE, Abromowitch M, Bayever E, Harper JL, Coccia PF.
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [Abstract] [Full Text] [Related]

  • 5. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B, Weisdorf DJ, Kim T, Kersey JH, Ramsay NK.
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [Abstract] [Full Text] [Related]

  • 6. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients.
    Cahn JY, Bordigoni P, Souillet G, Pico JL, Plouvier E, Reiffers J, Benz-Lemoine E, Bergerat JP, Lutz P, Colombat P.
    Bone Marrow Transplant; 1991 Jan; 7(1):1-4. PubMed ID: 2043871
    [Abstract] [Full Text] [Related]

  • 7. The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia.
    Wang C, Qiao Z, Yang L, Ma L, Zhang H, Zhang J.
    Chin Med J (Engl); 1996 Apr; 109(4):304-7. PubMed ID: 8758293
    [Abstract] [Full Text] [Related]

  • 8. High-dose cytosine arabinoside and fractionated total body irradiation as a preparative regimen for the treatment of children with acute lymphoblastic leukemia and Down syndrome by allogeneic bone marrow transplantation.
    Conter V, D'Angelo P, Rizzari C, Jankovic M, Dampier C, Masera G, Johnson FL.
    Bone Marrow Transplant; 1996 Feb; 17(2):287-9. PubMed ID: 8640182
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE, Horan JT, Liesveld JL, Abboud CN, Zwetsch LM, Senf ES, Constine LS, Raubertas RF, Passarell JA, DiPersio JF.
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
    Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W, Fyles G, Tejpar I, Loach D, Minden M, Messner H, Lipton JH.
    Bone Marrow Transplant; 2007 Sep; 40(5):423-30. PubMed ID: 17603516
    [Abstract] [Full Text] [Related]

  • 11. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
    Rubin CM, Mick R, Johnson FL.
    Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
    [Abstract] [Full Text] [Related]

  • 12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 13. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 14. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan).
    Deconinck E, Cahn JY, Milpied N, Jouet JP, Vernant JP, Esperou H, Lioure B, Bordigoni P, Leblond V, Troussard X, Caillot D, Cordonnier JM, Hervé P.
    Bone Marrow Transplant; 1997 Nov; 20(9):731-5. PubMed ID: 9384474
    [Abstract] [Full Text] [Related]

  • 15. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
    Belkacémi Y, Ozsahin M, Rio B, Laporte JP, Leblond V, Pène F, Laugier A.
    Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
    [Abstract] [Full Text] [Related]

  • 16. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C, Aversa F, Raymondi C, Marsella AR, Panizza BM, Perrucci E, Piro F, Maranzano E, Lupattelli M, Martelli MF, Latini P.
    Cancer J Sci Am; 1996 Dec; 2(6):330-4. PubMed ID: 9166553
    [Abstract] [Full Text] [Related]

  • 18. Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey.
    Weyman C, Graham-Pole J, Emerson S, August C, Champlin R, Coccia P, Fay J, Harris R, Koch P, Johnson L.
    Bone Marrow Transplant; 1993 Jan; 11(1):43-50. PubMed ID: 8431710
    [Abstract] [Full Text] [Related]

  • 19. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate.
    Fyles GM, Messner HA, Lockwood G, Curtis JE, Rider W, Minden MD, Meharchand JM, Lipton J, Tritchler D, Van Dyk J.
    Bone Marrow Transplant; 1991 Dec; 8(6):453-63. PubMed ID: 1790425
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
    Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, Dipersio J, Adkins D.
    Biol Blood Marrow Transplant; 2004 May; 10(5):310-9. PubMed ID: 15111930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.